In 2022, in the WHO classification, this category was termed “Myeloid/lymphoid neoplasms with eosinophilia (M/LN-eo) and defining gene rearrangements” and “Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions” (M/LN-eo with TK-gene fusions) in the ICC 2022. This evidence concerns the gene TKT and lymphoid neoplasm.